Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2023-04-14 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司独立董事关于2022年度对外担保情况及关联方占用资金情况的专项说明及独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion from the independent directors regarding the company's external guarantees and related party fund occupation for the year 2022. It references regulatory guidelines and confirms no external guarantees or related party fund occupation occurred in 2022. The document is short (563 characters) and serves as a formal attestation or certification by independent directors rather than a full audit or annual report. It does not contain financial statements or detailed audit results but is a regulatory compliance statement. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit-related disclosures and independent opinions on specific financial risks, rather than a full annual report or regulatory filing. FY 2022
2023-04-14 Chinese
奥锐特药业股份有限公司截至2022年12月31日止前次募集资金使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "前次募集资金使用情况鉴证报告" which translates to "Previous Fundraising Usage Verification Report." It includes a verification report by a certified public accountant and a detailed report on the use of previously raised funds up to December 31, 2022. The document references compliance with the China Securities Regulatory Commission guidelines for issuance-related reports. It contains detailed financial data on fundraising amounts, usage, investment projects, and benefits realized from the investments. The presence of an auditor's verification report and detailed financial data on fundraising usage indicates this is an Audit Report / Information document rather than a full Annual Report or other category. The document length (6367 characters) and content confirm it is a standalone audit-related report on fundraising usage, not an announcement or a summary. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2022
2023-04-14 Chinese
奥锐特药业股份有限公司关于公司及子公司向银行及其他融资机构申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from the company's board regarding the application for a comprehensive credit facility (授信额度) from banks and other financing institutions. It details the authorization for the company and its subsidiaries to apply for credit lines up to a specified amount and the delegation of authority to execute related financing documents. There is no financial data, report, or detailed financial statements included. The document is a financing update about capital structure and credit facilities, fitting the Capital/Financing Update category.
2023-04-14 Chinese
奥锐特药业股份有限公司独立董事候选人声明（陈应春）
Board/Management Information Classification · 95% confidence The document is a declaration statement by an independent director candidate confirming qualifications, independence, and compliance with relevant laws and regulations. It does not contain financial data, audit results, or management discussion. It is not an announcement of voting results or a proxy solicitation. It is a formal statement related to board/management information, specifically about a director candidate's qualifications and independence. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on director candidacy, not a full report or announcement of a meeting result.
2023-04-14 Chinese
奥锐特药业股份有限公司2022年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report'. It references auditing standards and the responsibility of the company's board and auditors regarding internal control over financial reporting as of December 31, 2022. The document contains an auditor's opinion on the effectiveness of internal controls, which is typical of a standalone audit report rather than a full annual report or other filings. The length is short (773 characters) but the content is substantive and specific to an audit report on internal controls, not merely an announcement or certification. Therefore, it fits the category of Audit Report / Information (AR). FY 2022
2023-04-14 Chinese
奥锐特药业股份有限公司独立董事候选人声明（苏为科）
Board/Management Information Classification · 95% confidence The document is a declaration statement by an independent director candidate, detailing qualifications, independence criteria, and compliance with regulatory requirements. It references laws, regulations, and stock exchange rules related to director qualifications and independence. There is no financial data, no report or meeting materials, no voting results, no management changes, and no financial performance information. The document is a formal statement related to governance and compliance, specifically about the candidacy and qualifications of an independent director. This fits best under Board/Management Information (MANG), which covers announcements related to changes or appointments in the company's board or senior management.
2023-04-14 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.